Solara Active Pharma Sciences issues Second and Final Call Money Notice
Solara Active Pharma Sciences Limited is making a Second and Final Call for ₹112.50 per partly paid-up equity share. The payment period is from April 23 to May 7, 2026. Advertisements were published on April 8, 2026.
This is a critical step for the company to realize the funds from its rights issue. Failure of shareholders to pay could impact the company's capital structure and future plans. However, the impact is limited to the shareholders who hold these specific partly paid-up shares.
The announcement is a routine procedural step for the company regarding its rights issue, informing shareholders about the final call for payment. It does not contain any new financial performance data or strategic changes that would significantly alter the company's outlook.
Solara Active Pharma Sciences Limited has issued a Second and Final Call Money Notice to the holders of its partly paid-up Rights Equity Shares. The call is for an amount of ₹112.50 per equity share, comprising ₹3.00 towards face value and ₹109.50 towards securities premium. The notice was approved by the Rights Issue Committee on March 24, 2026, with a record date of April 2, 2026, to determine eligible shareholders. Electronic notices were dispatched on April 6, 2026, to shareholders with registered email addresses, and physical copies were dispatched on April 7, 2026, to those without registered emails. The payment period for this second and final call is 15 days, from April 23, 2026, to May 7, 2026. Shareholders can make payments through online or physical ASBA, or via 3-in-1 trading-demat-bank accounts. Detailed instructions and FAQs are available on the company's website and the RTA's website. The company also published advertisements regarding this notice in 'Business Standard' and 'Pratahkal' on April 8, 2026, and these are available on the company's investor relations page.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.